Biodesix (BDSX)
(Delayed Data from NSDQ)
$1.66 USD
+0.04 (2.47%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $1.67 +0.01 (0.60%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BDSX 1.66 +0.04(2.47%)
Will BDSX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BDSX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDSX
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
BDSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?
Other News for BDSX
Biodesix Named to Inc. Magazine’s 2024 “Best Workplaces”
Biodesix to Participate in Two Investor Conferences in June
Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting
Buy Rating Justified by Biodesix’s Market Leadership and Strong Growth Prospects
Biodesix initiated with bullish view at TD Cowen, here's why